Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Calls For U.S. Contract To Guarantee Tamiflu Stockpile

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS is in discussions to purchase enough of the influenza treatment to cover a total of 3% of the U.S. population, Roche tells House hearing on pandemic preparedness. Other countries already have purchase commitments that would cover 20% to 40% of their populations.

You may also be interested in...



SEC Seeks Vaccine Manufacturer Input On Pediatric Stockpile Accounting

Securities & Exchange Commission regulations on revenue recognition are preventing childhood vaccine manufacturers from selling product to a government stockpile. Rep. Waxman declares support for a special exemption for vaccine makers.

FDA Studying Effects Of Radio-Frequency ID Technology On Liquid Drugs

The agency has seen "tremendous progress" in the move toward electronic product codes and use of radio-frequency identification, FDA says in its annual counterfeit drug update. FDA initiated 58 counterfeit drug investigations in 2004, up from 30 the previous year.

Population-Wide Smallpox Vaccination Urged At Senate Hearing

Smallpox vaccination should be reinstated for the entire U.S. population, MIT’s Deutch suggests. Additional research on other biological threats is called for; federal funding is recommended instead of relying on industry initiative, due to lack of market incentives.

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel